Online inquiry

IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8051MR)

This product GTTS-WQ8051MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8051MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2685MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ3492MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ5494MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ8501MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ5621MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ13616MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ8753MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ5725MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW